NEJM published two phase 3 trials of reta in obstructive sleep apnea on Oct 20 (TRIUMPH-1-OSA, 243 adults without type 2 diabetes; TRIUMPH-2-OSA, 448 with it). People started at about 58 breathing events an hour in trial 1. By 80 weeks, that fell by up to 34 an hour vs 9.9 on placebo, and weight fell up to 22% vs 4.8%. In trial 2 the drops were up to 25 vs 10.3. Stomach side effects were most common. Lilly funded both, and reta is still not approved anywhere. Results in a trial aren't a plan; talk to your doctor. #sleepapnea #reta #glp1 #peps #regen